Edition:
United States

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives


Tuesday, 8 Jan 2019 08:30am EST 

Jan 8 (Reuters) - Moderna Inc ::MODERNA ANNOUNCES RECENT PROGRESS IN ITS IMMUNO-ONCOLOGY AND RARE DISEASE PROGRAMS AND HIGHLIGHTS CORPORATE OBJECTIVES.MODERNA INC - IND AMENDMENT SUBMITTED TO FDA FOR A PHASE 2 COHORT OF OX40L (MRNA-2416) TO TREAT ADVANCED OVARIAN CARCINOMA.MODERNA INC - PLANNING FOR A PHASE 2 STUDY OF PERSONALIZED CANCER VACCINE (MRNA-4157) INITIATED TOGETHER WITH STRATEGIC COLLABORATOR MERCK.MODERNA INC - EXPECT OUR CASH, CASH EQUIVALENTS, AND INVESTMENTS IN MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 TO BE ABOUT $1.7 BILLION.